🫂Even with significant advancements in end-of-life and palliative care, challenges persist in effectively managing pain for individuals with advanced-stage cancer and in supporting veterans grappling with PTSD.
📊Recent studies indicate that psychedelics are promising in alleviating emotional distress at life's end. Consequently, this area is drawing significant investment, with its value potentially hitting $6.85 billion by 2027. Yet, as of 2023, the range of psychopharmacological treatments available for clinicians and patients in such settings is still limited.
💜In this post, we'll explore the compelling reasons to consider the integration of psychedelics in patient-centered care.
